BOSTON IMMUNE TECHNOLOGIES & THERAPEUTICS

boston-immune-technologies-therapeutics-logo

BITT has developed a platform for targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and the potent population of TNFR2 Tregs in the tumor microenvironment.

#People #Financial #Website #More

BOSTON IMMUNE TECHNOLOGIES & THERAPEUTICS

Industry:
Biotechnology Therapeutics

Founded:
2011-01-01

Address:
Winchester, Virginia, United States

Country:
United States

Website Url:
http://www.bostonimmunetech.com

Total Employee:
1+

Status:
Active

Total Funding:
10 M USD

Technology used in webpage:
SPF Content Delivery Network Font Awesome Microsoft Exchange Online Office 365 Mail IPv6 BootstrapCDN Cloudflare Hosting Cloudflare DNS



Current Advisors List

sheila-mikhail_image

Sheila Mikhail Business Advisor @ Boston Immune Technologies & Therapeutics
Advisor

Current Employees Featured

russell-lamontagne_image

Russell LaMontagne
Russell LaMontagne Co-Founder, Chief Executive Officer & President @ Boston Immune Technologies & Therapeutics
Co-Founder, Chief Executive Officer & President
2014-02-01

Founder


denise-faustman_image

Denise Faustman

russell-lamontagne_image

Russell LaMontagne

Investors List

beigene_image

BeiGene

BeiGene investment in Series A - Boston Immune Technologies & Therapeutics

hatteras-venture-partners_image

Hatteras Venture Partners

Hatteras Venture Partners investment in Series A - Boston Immune Technologies & Therapeutics

Official Site Inspections

http://www.bostonimmunetech.com Semrush global rank: 5.42 M Semrush visits lastest month: 1.56 K

  • Host name: 186.27.212.35.bc.googleusercontent.com
  • IP address: 35.212.27.186
  • Location: United States
  • Latitude: 38.6583
  • Longitude: -77.2481
  • Timezone: America/New_York

Loading ...

More informations about "Boston Immune Technologies & Therapeutics"

Boston Immune Technologies and Therapeutics | LinkedIn

Boston Immune Technologies and Therapeutics Biotechnology Research Boston, …See details»

Boston Immune Technologies & Therapeutics - Crunchbase

View contacts for Boston Immune Technologies & Therapeutics to access new leads and …See details»

BITT | Boston Immune Technologies & Therapeutics

Order cheap Hydrochlorothiazide High Blood Pressure cheap no prescription Discuss the risks …See details»

Boston Immune Technologies and Therapeutics, Inc.

Website: https://www.bostonimmunetech.com. Develops a proprietary discovery platform for …See details»

Boston Immune Technologies & Therapeutics, Inc.: Drug pipelines ...

Jun 21, 2023 Explore Boston Immune Technologies & Therapeutics, Inc. with its drug …See details»

Boston Immune Technologies & Therapeutics Inc · Boston Immune ...

BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS INC. (doing business as …See details»

Boston Immune Technologies & Therapeutics - Craft

Boston Immune Technologies & Therapeutics $10 m in total funding,. See insights on Boston …See details»

Boston Immune Technologies and Therapeutics - ZoomInfo

Aug 18, 2023 BITT To Present Update on CD40 Program at AAI 2023 BOSTON--(BUSINESS …See details»

Media | BITT - Boston Immune Tech

August 16, 2024 BITT Announced CD40 Otsuka Research and Exclusivity Agreement and …See details»

Boston Immune Technologies and Therapeutics, Inc.

Oct 29, 2017 www.bostonimmunetech.com : disclaimers Any reproduction or further …See details»

BITT Announced CD40 Otsuka Research and Exclusivity Agreement …

Aug 16, 2024 BITT has begun clinical trials for BIR2101, its lead candidate, which is a …See details»

Boston Immune Technologies and Therapeutics and BeiGene Enter …

Feb 17, 2021 Exclusive license for Asia (ex-Japan), Australia and New Zealand; Parties plan …See details»

BITT Announced CD40 Otsuka Research and Exclusivity Agreement …

Aug 16, 2024 Learn more at: www.bostonimmunetech.com. Contacts. Karl Schmieder …See details»

BITT Announces NIH SBIR Award and New Board Member

Dec 13, 2021 BITT has received a SBIR grant from the National Cancer Institute at the US …See details»

BITT Announces NIH Award for Advancement of Anti-CD40 Antibody

Aug 31, 2023 Boston Immune Technologies and Therapeutics, Inc. (BITT), a clinical-stage …See details»

Boston Immune Technologies and Therapeutics Raises $10M …

Mar 17, 2021 For more information, visit our website at www.bostonimmunetech.com. …See details»

Science | BITT - Boston Immune Tech

Science. would like to process and share personal data (e.g., mobile ad id) and data about …See details»

Selexis and Boston Immune Technologies and Therapeutics (BITT) …

Mar 9, 2021 GENEVA & BOSTON--(BUSINESS WIRE)--Mar 9, 2021-- Selexis SA and …See details»

Boston Immune Technologies and Therapeutics and BeiGene Enter …

Feb 17, 2021 For more information, visit our website at www.bostonimmunetech.com. About …See details»

Russell LaMontagne - President & Chief Executive Officer at …

Oct 19, 2024 Russell LaMontagne contact details: Email address: …See details»

linkstock.net © 2022. All rights reserved